 Lee Newman
Concepts (513)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health | 28 | 2022 | 164 | 12.520 |
Why?
| | Small Business | 14 | 2022 | 51 | 7.740 |
Why?
| | Saccharum | 14 | 2023 | 59 | 6.780 |
Why?
| | Berylliosis | 36 | 2018 | 177 | 5.920 |
Why?
| | Occupational Exposure | 30 | 2023 | 256 | 5.880 |
Why?
| | Farmers | 10 | 2022 | 42 | 5.710 |
Why?
| | Beryllium | 30 | 2018 | 146 | 4.930 |
Why?
| | Renal Insufficiency, Chronic | 12 | 2023 | 486 | 4.440 |
Why?
| | Occupational Injuries | 7 | 2023 | 46 | 3.830 |
Why?
| | Workplace | 25 | 2023 | 220 | 3.820 |
Why?
| | Agricultural Workers' Diseases | 5 | 2020 | 23 | 2.820 |
Why?
| | Health Promotion | 11 | 2021 | 686 | 2.700 |
Why?
| | Occupational Diseases | 9 | 2019 | 128 | 2.520 |
Why?
| | Heat Stress Disorders | 5 | 2023 | 40 | 2.480 |
Why?
| | Agriculture | 6 | 2020 | 71 | 2.340 |
Why?
| | Workers' Compensation | 4 | 2019 | 27 | 1.960 |
Why?
| | Hot Temperature | 7 | 2023 | 304 | 1.870 |
Why?
| | Organizational Culture | 5 | 2022 | 119 | 1.680 |
Why?
| | Guatemala | 12 | 2021 | 266 | 1.660 |
Why?
| | Leadership | 6 | 2022 | 295 | 1.660 |
Why?
| | Sarcoidosis | 13 | 2012 | 135 | 1.530 |
Why?
| | Glomerular Filtration Rate | 5 | 2021 | 604 | 1.470 |
Why?
| | Safety Management | 6 | 2021 | 109 | 1.450 |
Why?
| | Kidney | 6 | 2021 | 1184 | 1.310 |
Why?
| | Humans | 132 | 2023 | 114935 | 1.260 |
Why?
| | Creatinine | 6 | 2023 | 424 | 1.240 |
Why?
| | Absenteeism | 2 | 2018 | 40 | 1.160 |
Why?
| | Adult | 56 | 2021 | 30608 | 1.130 |
Why?
| | Lymphocytes | 4 | 2018 | 333 | 1.110 |
Why?
| | Chronic Disease | 25 | 2018 | 1593 | 1.110 |
Why?
| | Health Behavior | 5 | 2022 | 704 | 1.110 |
Why?
| | Colorado | 19 | 2023 | 4091 | 0.990 |
Why?
| | Male | 68 | 2023 | 55663 | 0.960 |
Why?
| | Industry | 4 | 2019 | 65 | 0.930 |
Why?
| | Dehydration | 3 | 2020 | 40 | 0.890 |
Why?
| | Air Pollutants | 4 | 2020 | 244 | 0.880 |
Why?
| | Environmental Monitoring | 5 | 2022 | 254 | 0.860 |
Why?
| | Occupational Stress | 1 | 2023 | 35 | 0.840 |
Why?
| | Point-of-Care Testing | 2 | 2023 | 29 | 0.830 |
Why?
| | Longitudinal Studies | 10 | 2021 | 2382 | 0.820 |
Why?
| | Middle Aged | 50 | 2021 | 26806 | 0.820 |
Why?
| | Acute Kidney Injury | 2 | 2019 | 638 | 0.810 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 773 | 0.760 |
Why?
| | Efficiency | 2 | 2018 | 84 | 0.740 |
Why?
| | Risk Factors | 23 | 2021 | 8637 | 0.730 |
Why?
| | Arsenic | 1 | 2021 | 37 | 0.730 |
Why?
| | Anemia | 1 | 2021 | 144 | 0.710 |
Why?
| | Cross-Sectional Studies | 12 | 2021 | 4407 | 0.710 |
Why?
| | Neurophysins | 1 | 2020 | 5 | 0.710 |
Why?
| | Capacity Building | 1 | 2020 | 51 | 0.690 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 217 | 0.690 |
Why?
| | Sleep | 2 | 2023 | 632 | 0.680 |
Why?
| | Glycopeptides | 1 | 2020 | 43 | 0.680 |
Why?
| | Biomarkers | 6 | 2020 | 3418 | 0.680 |
Why?
| | Vasopressins | 1 | 2020 | 56 | 0.680 |
Why?
| | Inhalation Exposure | 1 | 2020 | 97 | 0.680 |
Why?
| | Respiratory Hypersensitivity | 4 | 2004 | 60 | 0.670 |
Why?
| | HLA-DP Antigens | 6 | 2011 | 32 | 0.670 |
Why?
| | Protein Precursors | 1 | 2020 | 119 | 0.660 |
Why?
| | Cell Proliferation | 5 | 2018 | 2199 | 0.640 |
Why?
| | Presenteeism | 1 | 2018 | 5 | 0.640 |
Why?
| | Female | 57 | 2021 | 59580 | 0.630 |
Why?
| | Smoking | 8 | 2021 | 1391 | 0.630 |
Why?
| | Veterinarians | 1 | 2018 | 11 | 0.620 |
Why?
| | Young Adult | 13 | 2021 | 10478 | 0.610 |
Why?
| | Body Composition | 1 | 2021 | 585 | 0.600 |
Why?
| | Accidents, Occupational | 2 | 2015 | 14 | 0.590 |
Why?
| | Drug Utilization | 1 | 2018 | 167 | 0.590 |
Why?
| | Text Messaging | 1 | 2020 | 154 | 0.590 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2011 | 966 | 0.580 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 87 | 0.570 |
Why?
| | Metabolic Diseases | 1 | 2018 | 96 | 0.570 |
Why?
| | Environmental Exposure | 8 | 2013 | 377 | 0.570 |
Why?
| | Extraction and Processing Industry | 2 | 2014 | 11 | 0.570 |
Why?
| | Work Performance | 1 | 2017 | 6 | 0.570 |
Why?
| | Professional Role | 1 | 2018 | 152 | 0.560 |
Why?
| | Guidelines as Topic | 1 | 2018 | 244 | 0.550 |
Why?
| | Renal Insufficiency | 1 | 2018 | 136 | 0.550 |
Why?
| | Mass Screening | 3 | 2022 | 1011 | 0.540 |
Why?
| | Lymphocyte Activation | 16 | 2014 | 1045 | 0.540 |
Why?
| | Health Policy | 1 | 2019 | 334 | 0.530 |
Why?
| | Sarcoidosis, Pulmonary | 8 | 2010 | 58 | 0.530 |
Why?
| | Federal Government | 1 | 2016 | 26 | 0.530 |
Why?
| | CpG Islands | 1 | 2015 | 117 | 0.510 |
Why?
| | Antigens, Bacterial | 4 | 2012 | 112 | 0.500 |
Why?
| | Food Industry | 1 | 2015 | 14 | 0.500 |
Why?
| | Safety | 2 | 2015 | 297 | 0.500 |
Why?
| | Chronic Pain | 1 | 2018 | 211 | 0.490 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2015 | 1134 | 0.490 |
Why?
| | Guideline Adherence | 1 | 2018 | 490 | 0.480 |
Why?
| | United States | 16 | 2022 | 12211 | 0.460 |
Why?
| | Occupational Health Services | 1 | 2014 | 31 | 0.460 |
Why?
| | Oil and Gas Fields | 1 | 2014 | 32 | 0.450 |
Why?
| | Population Surveillance | 3 | 2018 | 392 | 0.450 |
Why?
| | Lung | 11 | 2019 | 3593 | 0.440 |
Why?
| | Natural Gas | 4 | 2014 | 27 | 0.430 |
Why?
| | Granuloma, Respiratory Tract | 4 | 2007 | 12 | 0.430 |
Why?
| | Life Style | 1 | 2015 | 430 | 0.410 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 200 | 0.410 |
Why?
| | Aged | 22 | 2021 | 19122 | 0.410 |
Why?
| | Influenza, Human | 2 | 2022 | 546 | 0.400 |
Why?
| | Hypertension | 1 | 2020 | 1059 | 0.400 |
Why?
| | DNA Methylation | 1 | 2015 | 496 | 0.380 |
Why?
| | Mycobacterium | 3 | 2009 | 103 | 0.380 |
Why?
| | Latin America | 2 | 2022 | 69 | 0.380 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 413 | 0.380 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1133 | 0.380 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 546 | 0.380 |
Why?
| | Mass Spectrometry | 1 | 2014 | 633 | 0.370 |
Why?
| | Logistic Models | 7 | 2022 | 1844 | 0.370 |
Why?
| | Air Pollution, Indoor | 3 | 2019 | 108 | 0.360 |
Why?
| | Mental Disorders | 1 | 2018 | 891 | 0.360 |
Why?
| | Macrophages | 2 | 2015 | 1266 | 0.360 |
Why?
| | Mycobacterium Infections | 2 | 2012 | 61 | 0.360 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1177 | 0.350 |
Why?
| | HLA-DP beta-Chains | 7 | 2014 | 76 | 0.350 |
Why?
| | Macrophages, Alveolar | 2 | 2004 | 351 | 0.350 |
Why?
| | Ferritins | 2 | 2014 | 52 | 0.350 |
Why?
| | Prevalence | 3 | 2021 | 2252 | 0.350 |
Why?
| | Electrolytes | 2 | 2020 | 55 | 0.340 |
Why?
| | Health Status | 3 | 2021 | 721 | 0.330 |
Why?
| | B-Lymphocytes | 1 | 2014 | 772 | 0.330 |
Why?
| | Temperature | 2 | 2023 | 576 | 0.330 |
Why?
| | Perception | 3 | 2021 | 311 | 0.320 |
Why?
| | Delivery of Health Care | 1 | 2016 | 834 | 0.320 |
Why?
| | Data Collection | 1 | 2011 | 623 | 0.320 |
Why?
| | T-Lymphocytes | 3 | 2014 | 1749 | 0.320 |
Why?
| | HLA Antigens | 4 | 2010 | 224 | 0.310 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1440 | 0.310 |
Why?
| | Pulmonary Fibrosis | 2 | 2005 | 323 | 0.310 |
Why?
| | HLA-DR Antigens | 7 | 2010 | 220 | 0.300 |
Why?
| | Insurance Claim Reporting | 2 | 2018 | 22 | 0.300 |
Why?
| | Police | 1 | 2007 | 30 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 8 | 2010 | 2102 | 0.290 |
Why?
| | Program Development | 2 | 2020 | 345 | 0.290 |
Why?
| | Internet | 1 | 2011 | 599 | 0.290 |
Why?
| | Methamphetamine | 1 | 2007 | 51 | 0.290 |
Why?
| | Immunization | 3 | 2005 | 402 | 0.280 |
Why?
| | Sensitivity and Specificity | 7 | 2023 | 1700 | 0.280 |
Why?
| | Prospective Studies | 5 | 2020 | 6218 | 0.280 |
Why?
| | Case-Control Studies | 10 | 2018 | 3008 | 0.280 |
Why?
| | Respiratory Protective Devices | 2 | 2007 | 11 | 0.280 |
Why?
| | Wyoming | 2 | 2018 | 17 | 0.280 |
Why?
| | Apoptosis | 4 | 2005 | 2371 | 0.270 |
Why?
| | Pilot Projects | 2 | 2021 | 1372 | 0.270 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 139 | 0.270 |
Why?
| | Cohort Studies | 6 | 2019 | 4903 | 0.270 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 2005 | 1 | 0.260 |
Why?
| | Proteomics | 2 | 2011 | 844 | 0.260 |
Why?
| | Plutonium | 1 | 2005 | 2 | 0.260 |
Why?
| | Neopterin | 2 | 2003 | 9 | 0.260 |
Why?
| | Chemical Industry | 1 | 2005 | 9 | 0.250 |
Why?
| | Particulate Matter | 2 | 2020 | 185 | 0.250 |
Why?
| | Antigen Presentation | 4 | 2014 | 189 | 0.250 |
Why?
| | Research | 3 | 2018 | 395 | 0.250 |
Why?
| | Bronchoalveolar Lavage Fluid | 8 | 2009 | 590 | 0.250 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2006 | 76 | 0.240 |
Why?
| | Electronic Health Records | 1 | 2011 | 802 | 0.240 |
Why?
| | Pandemics | 3 | 2022 | 1325 | 0.240 |
Why?
| | Nuclear Warfare | 1 | 2004 | 5 | 0.240 |
Why?
| | Research Design | 2 | 2022 | 932 | 0.240 |
Why?
| | Cadmium | 2 | 2022 | 58 | 0.230 |
Why?
| | Age of Onset | 1 | 2006 | 448 | 0.230 |
Why?
| | Risk Assessment | 5 | 2021 | 2975 | 0.220 |
Why?
| | Residence Characteristics | 2 | 2018 | 275 | 0.220 |
Why?
| | Vaccination | 1 | 2011 | 1205 | 0.220 |
Why?
| | Climate Change | 2 | 2022 | 125 | 0.220 |
Why?
| | Pneumoconiosis | 2 | 2004 | 12 | 0.220 |
Why?
| | Prognosis | 5 | 2020 | 3344 | 0.210 |
Why?
| | Volcanic Eruptions | 1 | 2022 | 6 | 0.210 |
Why?
| | Inflammation Mediators | 3 | 2014 | 476 | 0.210 |
Why?
| | Ventilation | 2 | 2019 | 32 | 0.210 |
Why?
| | Metals, Heavy | 1 | 2022 | 19 | 0.200 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 524 | 0.200 |
Why?
| | Metals | 2 | 2004 | 107 | 0.200 |
Why?
| | Immunity, Active | 1 | 2002 | 9 | 0.200 |
Why?
| | Health Surveys | 2 | 2018 | 443 | 0.200 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 353 | 0.200 |
Why?
| | Crops, Agricultural | 2 | 2019 | 28 | 0.200 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 321 | 0.200 |
Why?
| | Aged, 80 and over | 8 | 2011 | 6364 | 0.200 |
Why?
| | Models, Immunological | 1 | 2002 | 92 | 0.190 |
Why?
| | Calculi | 1 | 2021 | 16 | 0.190 |
Why?
| | Organizational Innovation | 1 | 2022 | 133 | 0.190 |
Why?
| | Cotinine | 1 | 2021 | 69 | 0.190 |
Why?
| | Time Factors | 4 | 2019 | 6125 | 0.180 |
Why?
| | Nickel | 1 | 2021 | 50 | 0.180 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1317 | 0.180 |
Why?
| | Virus Diseases | 1 | 2022 | 196 | 0.180 |
Why?
| | Beverages | 1 | 2020 | 60 | 0.180 |
Why?
| | Policy | 1 | 2021 | 137 | 0.180 |
Why?
| | Noise, Occupational | 1 | 2019 | 5 | 0.170 |
Why?
| | Kidney Function Tests | 1 | 2020 | 140 | 0.170 |
Why?
| | Social Support | 1 | 2023 | 528 | 0.170 |
Why?
| | HLA-DQ Antigens | 4 | 2010 | 176 | 0.170 |
Why?
| | Adolescent | 7 | 2021 | 17829 | 0.170 |
Why?
| | Hemoglobins | 1 | 2021 | 314 | 0.170 |
Why?
| | Sri Lanka | 1 | 2019 | 7 | 0.170 |
Why?
| | Global Health | 2 | 2016 | 288 | 0.170 |
Why?
| | Specific Gravity | 1 | 2019 | 11 | 0.170 |
Why?
| | Central America | 1 | 2019 | 16 | 0.170 |
Why?
| | Nutritional Status | 1 | 2021 | 286 | 0.160 |
Why?
| | Heat-Shock Response | 1 | 2019 | 46 | 0.160 |
Why?
| | Body Mass Index | 2 | 2018 | 1961 | 0.160 |
Why?
| | Lung Diseases, Interstitial | 1 | 2004 | 515 | 0.160 |
Why?
| | India | 1 | 2019 | 134 | 0.160 |
Why?
| | Neoplasms | 3 | 2018 | 2106 | 0.160 |
Why?
| | Blood Proteins | 2 | 2011 | 233 | 0.160 |
Why?
| | Climate | 1 | 2019 | 85 | 0.160 |
Why?
| | Interferon-gamma | 5 | 2015 | 723 | 0.160 |
Why?
| | Unemployment | 1 | 2018 | 39 | 0.160 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.160 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 11 | 0.160 |
Why?
| | Survivorship | 1 | 2018 | 39 | 0.160 |
Why?
| | Digestive System Diseases | 1 | 2018 | 23 | 0.160 |
Why?
| | False Positive Reactions | 1 | 2018 | 109 | 0.160 |
Why?
| | Granuloma | 2 | 2014 | 84 | 0.150 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 23 | 0.150 |
Why?
| | Urologic Diseases | 1 | 2018 | 35 | 0.150 |
Why?
| | Asbestosis | 2 | 2011 | 12 | 0.150 |
Why?
| | Educational Status | 1 | 2020 | 409 | 0.150 |
Why?
| | Models, Psychological | 1 | 2020 | 296 | 0.150 |
Why?
| | Job Satisfaction | 1 | 2020 | 168 | 0.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 928 | 0.150 |
Why?
| | Reference Standards | 1 | 2018 | 159 | 0.150 |
Why?
| | Adaptation, Physiological | 1 | 2022 | 483 | 0.150 |
Why?
| | Benchmarking | 1 | 2019 | 161 | 0.150 |
Why?
| | Cytokines | 3 | 2014 | 1843 | 0.150 |
Why?
| | Fever | 1 | 2019 | 279 | 0.150 |
Why?
| | Catalase | 2 | 2009 | 117 | 0.150 |
Why?
| | Self Report | 1 | 2021 | 696 | 0.150 |
Why?
| | Physical Exertion | 1 | 2019 | 211 | 0.150 |
Why?
| | Awareness | 1 | 2018 | 92 | 0.150 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1270 | 0.150 |
Why?
| | Epidemics | 1 | 2018 | 69 | 0.150 |
Why?
| | Arthritis | 1 | 2018 | 111 | 0.140 |
Why?
| | Employment | 1 | 2018 | 138 | 0.140 |
Why?
| | Air Pollutants, Occupational | 3 | 2007 | 27 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 140 | 0.140 |
Why?
| | Mice | 8 | 2019 | 14935 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2018 | 239 | 0.140 |
Why?
| | Diagnosis, Differential | 4 | 2004 | 1355 | 0.130 |
Why?
| | Immunity, Innate | 1 | 2002 | 724 | 0.130 |
Why?
| | Nuclear Energy | 1 | 2016 | 2 | 0.130 |
Why?
| | Nuclear Power Plants | 1 | 2016 | 2 | 0.130 |
Why?
| | HLA-DRB1 Chains | 6 | 2010 | 98 | 0.130 |
Why?
| | Community Health Planning | 1 | 2016 | 44 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1080 | 0.130 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 43 | 0.130 |
Why?
| | Motivation | 1 | 2020 | 495 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2019 | 350 | 0.130 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1996 | 83 | 0.130 |
Why?
| | Population Health | 1 | 2016 | 42 | 0.130 |
Why?
| | Linear Models | 1 | 2018 | 770 | 0.130 |
Why?
| | Cell Line | 2 | 2015 | 2640 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 937 | 0.130 |
Why?
| | Hypersensitivity | 2 | 2012 | 256 | 0.130 |
Why?
| | Cell Line, Transformed | 2 | 2014 | 133 | 0.130 |
Why?
| | Mast Cells | 1 | 1996 | 117 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2020 | 12544 | 0.120 |
Why?
| | Radiography, Thoracic | 4 | 2006 | 162 | 0.120 |
Why?
| | Medical Laboratory Personnel | 2 | 2006 | 7 | 0.120 |
Why?
| | Heart Diseases | 1 | 2018 | 330 | 0.120 |
Why?
| | Disease Progression | 5 | 2011 | 2392 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2018 | 206 | 0.120 |
Why?
| | Communication | 1 | 2020 | 749 | 0.120 |
Why?
| | Macrophage Activation | 1 | 2015 | 164 | 0.120 |
Why?
| | Community Health Services | 1 | 2016 | 212 | 0.120 |
Why?
| | Ions | 1 | 2014 | 59 | 0.120 |
Why?
| | Program Evaluation | 1 | 2018 | 824 | 0.120 |
Why?
| | Research Personnel | 1 | 2016 | 151 | 0.120 |
Why?
| | Fruit | 1 | 2015 | 128 | 0.110 |
Why?
| | Vegetables | 1 | 2015 | 133 | 0.110 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 138 | 0.110 |
Why?
| | Endotoxins | 2 | 2006 | 204 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1630 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2316 | 0.110 |
Why?
| | Allergens | 3 | 2006 | 417 | 0.110 |
Why?
| | Health Impact Assessment | 1 | 2013 | 7 | 0.110 |
Why?
| | Genotype | 6 | 2011 | 1775 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1721 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 904 | 0.110 |
Why?
| | Water Supply | 2 | 2016 | 70 | 0.100 |
Why?
| | Bacterial Proteins | 2 | 2009 | 739 | 0.100 |
Why?
| | Immunologic Memory | 2 | 2005 | 313 | 0.100 |
Why?
| | Cell Division | 2 | 2004 | 759 | 0.100 |
Why?
| | Maximum Allowable Concentration | 2 | 2019 | 14 | 0.100 |
Why?
| | Up-Regulation | 2 | 2006 | 812 | 0.100 |
Why?
| | Antigens, Fungal | 1 | 2012 | 25 | 0.100 |
Why?
| | Hydrocarbons | 1 | 2012 | 29 | 0.100 |
Why?
| | Paper | 1 | 2011 | 9 | 0.100 |
Why?
| | Personnel, Hospital | 1 | 2011 | 24 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 2 | 2005 | 384 | 0.100 |
Why?
| | Vital Capacity | 2 | 2019 | 257 | 0.100 |
Why?
| | Health Services Research | 1 | 2014 | 371 | 0.100 |
Why?
| | Pulmonary Gas Exchange | 2 | 2004 | 117 | 0.090 |
Why?
| | Glutamic Acid | 2 | 2003 | 211 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1400 | 0.090 |
Why?
| | Alleles | 4 | 2011 | 791 | 0.090 |
Why?
| | Forced Expiratory Volume | 2 | 2019 | 476 | 0.090 |
Why?
| | Schools, Veterinary | 1 | 2010 | 2 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2324 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 2817 | 0.090 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 70 | 0.090 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 946 | 0.090 |
Why?
| | Sulfasalazine | 1 | 2009 | 21 | 0.090 |
Why?
| | Mesalamine | 1 | 2009 | 8 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 299 | 0.080 |
Why?
| | Air Pollution | 1 | 2012 | 170 | 0.080 |
Why?
| | Animals | 9 | 2019 | 31837 | 0.080 |
Why?
| | Uveitis | 1 | 2010 | 115 | 0.080 |
Why?
| | Cell Separation | 2 | 2009 | 292 | 0.080 |
Why?
| | Silicosis | 1 | 1989 | 21 | 0.080 |
Why?
| | Alcohol Drinking | 1 | 2015 | 655 | 0.080 |
Why?
| | Latent Tuberculosis | 1 | 2009 | 64 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 620 | 0.080 |
Why?
| | Swimming Pools | 1 | 2007 | 5 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2006 | 2558 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2007 | 8 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2326 | 0.070 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2542 | 0.070 |
Why?
| | Crime | 1 | 2007 | 59 | 0.070 |
Why?
| | Spirometry | 3 | 2019 | 225 | 0.070 |
Why?
| | Animal Technicians | 2 | 2006 | 3 | 0.070 |
Why?
| | Water Microbiology | 1 | 2007 | 77 | 0.070 |
Why?
| | Influenza Vaccines | 1 | 2011 | 497 | 0.070 |
Why?
| | Aerosols | 1 | 2007 | 151 | 0.070 |
Why?
| | Cells, Cultured | 5 | 2009 | 3897 | 0.070 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 153 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 536 | 0.070 |
Why?
| | Transcription Factor AP-1 | 1 | 2006 | 80 | 0.070 |
Why?
| | Genetic Markers | 2 | 2010 | 322 | 0.070 |
Why?
| | Gene Dosage | 1 | 2006 | 134 | 0.070 |
Why?
| | Risk | 2 | 2007 | 815 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 648 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 612 | 0.060 |
Why?
| | RNA Precursors | 1 | 2006 | 136 | 0.060 |
Why?
| | Biopsy | 2 | 2005 | 1045 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 60 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2006 | 496 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 120 | 0.060 |
Why?
| | Radioisotopes | 1 | 2004 | 28 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1054 | 0.060 |
Why?
| | Exercise | 1 | 2015 | 1643 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2005 | 297 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2014 | 9105 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2005 | 136 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 530 | 0.060 |
Why?
| | HLA-DRB3 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| | HLA-DRB5 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| | fas Receptor | 1 | 2004 | 92 | 0.060 |
Why?
| | HLA-DRB4 Chains | 1 | 2003 | 6 | 0.060 |
Why?
| | Public Health | 2 | 2022 | 434 | 0.060 |
Why?
| | Odds Ratio | 3 | 2014 | 954 | 0.060 |
Why?
| | Phagocytes | 1 | 2004 | 90 | 0.060 |
Why?
| | HLA-DQ beta-Chains | 1 | 2003 | 58 | 0.060 |
Why?
| | Tuberculosis | 1 | 2006 | 241 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2003 | 47 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 495 | 0.050 |
Why?
| | Animals, Laboratory | 1 | 2003 | 13 | 0.050 |
Why?
| | Immunologic Tests | 1 | 2003 | 16 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 817 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1555 | 0.050 |
Why?
| | Physiological Phenomena | 1 | 2002 | 1 | 0.050 |
Why?
| | Disposable Equipment | 1 | 2002 | 15 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 637 | 0.050 |
Why?
| | Contraindications | 1 | 2002 | 85 | 0.050 |
Why?
| | Genetic Variation | 1 | 2007 | 876 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 119 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2006 | 593 | 0.050 |
Why?
| | Patch Tests | 1 | 2002 | 52 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2002 | 82 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2004 | 588 | 0.050 |
Why?
| | Epitopes | 1 | 2003 | 436 | 0.050 |
Why?
| | Nuclear Weapons | 2 | 2011 | 5 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 139 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 797 | 0.050 |
Why?
| | Radiography | 1 | 2003 | 819 | 0.050 |
Why?
| | Equipment Design | 1 | 2002 | 511 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 545 | 0.040 |
Why?
| | ROC Curve | 2 | 2003 | 448 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1856 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2019 | 8 | 0.040 |
Why?
| | Kidney Medulla | 1 | 2019 | 29 | 0.040 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2019 | 21 | 0.040 |
Why?
| | Infliximab | 2 | 2012 | 94 | 0.040 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 1988 | 0.040 |
Why?
| | Quality of Life | 2 | 2012 | 2359 | 0.040 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 61 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 915 | 0.040 |
Why?
| | Selection Bias | 1 | 2018 | 33 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2791 | 0.040 |
Why?
| | Organizational Case Studies | 1 | 2018 | 69 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1530 | 0.040 |
Why?
| | Cities | 1 | 2018 | 81 | 0.040 |
Why?
| | Health | 1 | 2018 | 74 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2223 | 0.040 |
Why?
| | Genetic Association Studies | 2 | 2010 | 345 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 995 | 0.040 |
Why?
| | Fibrosis | 1 | 2000 | 454 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 453 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2018 | 198 | 0.040 |
Why?
| | Cost of Illness | 1 | 2018 | 254 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2009 | 118 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 731 | 0.030 |
Why?
| | Observer Variation | 1 | 1997 | 297 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4427 | 0.030 |
Why?
| | Poverty | 1 | 2019 | 443 | 0.030 |
Why?
| | Community Health Nursing | 1 | 2016 | 57 | 0.030 |
Why?
| | Gene Frequency | 2 | 2010 | 481 | 0.030 |
Why?
| | Sanitation | 1 | 2016 | 50 | 0.030 |
Why?
| | Antibody Formation | 1 | 1997 | 267 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 1663 | 0.030 |
Why?
| | Antigens | 1 | 1997 | 318 | 0.030 |
Why?
| | Community Participation | 1 | 2016 | 116 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 309 | 0.030 |
Why?
| | Education, Nursing | 1 | 2016 | 78 | 0.030 |
Why?
| | Siblings | 2 | 2006 | 223 | 0.030 |
Why?
| | Asthma | 2 | 2019 | 2042 | 0.030 |
Why?
| | Mitochondria | 1 | 2019 | 751 | 0.030 |
Why?
| | Universities | 1 | 2016 | 339 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 936 | 0.030 |
Why?
| | Disease Susceptibility | 2 | 2000 | 316 | 0.030 |
Why?
| | Cleft Palate | 1 | 2014 | 46 | 0.030 |
Why?
| | Education, Medical | 1 | 2016 | 222 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2014 | 125 | 0.030 |
Why?
| | Neural Tube Defects | 1 | 2014 | 61 | 0.030 |
Why?
| | Interleukin-2 | 2 | 2005 | 419 | 0.030 |
Why?
| | Lung Diseases | 1 | 1999 | 703 | 0.030 |
Why?
| | Dyspnea | 2 | 2005 | 218 | 0.030 |
Why?
| | Pregnancy | 2 | 2014 | 5527 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2014 | 138 | 0.030 |
Why?
| | Politics | 1 | 2013 | 78 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2012 | 47 | 0.020 |
Why?
| | Pneumonia | 1 | 1997 | 568 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 34 | 0.020 |
Why?
| | Inflammation | 1 | 2002 | 2485 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2002 | 18 | 0.020 |
Why?
| | Finland | 1 | 2011 | 69 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 249 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 396 | 0.020 |
Why?
| | Netherlands | 1 | 2010 | 64 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2010 | 9 | 0.020 |
Why?
| | Premature Birth | 1 | 2014 | 276 | 0.020 |
Why?
| | Japan | 1 | 2010 | 87 | 0.020 |
Why?
| | Toxoplasma | 1 | 2010 | 30 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 227 | 0.020 |
Why?
| | Salmonella enterica | 1 | 2010 | 49 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 1989 | 50 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2009 | 153 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 1801 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 1989 | 56 | 0.020 |
Why?
| | Demography | 1 | 2009 | 262 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 1897 | 0.020 |
Why?
| | Halogens | 1 | 2007 | 13 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 665 | 0.020 |
Why?
| | Codon | 1 | 2007 | 86 | 0.020 |
Why?
| | Tuberculin | 1 | 2006 | 6 | 0.020 |
Why?
| | Decision Making | 1 | 2013 | 781 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2009 | 295 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1022 | 0.020 |
Why?
| | Disinfection | 1 | 2007 | 106 | 0.020 |
Why?
| | Placebos | 1 | 2006 | 198 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 287 | 0.020 |
Why?
| | Eye | 1 | 2006 | 101 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2007 | 460 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2009 | 1087 | 0.020 |
Why?
| | Caspase 8 | 1 | 2005 | 43 | 0.020 |
Why?
| | Genetic Techniques | 1 | 2005 | 58 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2005 | 133 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2005 | 78 | 0.020 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 366 | 0.020 |
Why?
| | Metalloporphyrins | 1 | 2005 | 104 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2011 | 801 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 490 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1197 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 245 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 547 | 0.010 |
Why?
| | Abatacept | 1 | 2003 | 40 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 268 | 0.010 |
Why?
| | Radioallergosorbent Test | 1 | 2003 | 4 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 5035 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 76 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 58 | 0.010 |
Why?
| | Geography | 1 | 2003 | 181 | 0.010 |
Why?
| | Skin Tests | 1 | 2003 | 122 | 0.010 |
Why?
| | Genetic Testing | 1 | 2005 | 379 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2003 | 87 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2003 | 294 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1084 | 0.010 |
Why?
| | Autoantibodies | 1 | 1989 | 1354 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2001 | 45 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 183 | 0.010 |
Why?
| | Ceramics | 1 | 2001 | 16 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 242 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 325 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 353 | 0.010 |
Why?
| | Dogs | 1 | 2001 | 337 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 25 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 333 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 346 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 604 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 248 | 0.010 |
Why?
| | Liver | 1 | 2006 | 1634 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 867 | 0.010 |
Why?
| | Skin | 1 | 2002 | 659 | 0.010 |
Why?
| | Depression | 1 | 2005 | 1134 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1379 | 0.010 |
Why?
| | Bronchography | 1 | 1993 | 9 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 4635 | 0.010 |
Why?
| | Bronchiectasis | 1 | 1993 | 108 | 0.010 |
Why?
|
|
Newman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|